MOUNTAIN VIEW, California, February 25 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. announced today that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health (NIH) is now available. The data, that once again confirms the excellent safety and efficacy results previously reported, will be presented at the 2009 Genitourinary Cancers Symposium (GU) on February 26-28, 2009 in Orlando, Florida.
Abstracts from three different studies, where PROSTVAC(TM) has been evaluated as monotherapy or in combination with other therapies, are presented at the conference. The results from the studies support the further investigation in patients suffering from advanced prostate cancer.
The abstracts can be seen in full at ASCO's website: http://www.asco.org.
Study I (Abstract no. 108)
Study title: "A Phase II study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM with GM-CSF in Patients with PSA Progression After Local Therapy for Prostate Cancer."
In a study run by the Eastern Cooperative Oncology Group, the effect of PROSTVAC(TM) vaccination in patients with early stage recurrent prostate cancer was evaluated.
Results from the study demonstrate that by using PROSTVAC(TM) in an earlier disease setting, the vaccine has the ability to decrease the rate of rise in PSA levels indicating a potential delay in disease progression. In addition, the vaccine can be safely administered in a patient population with early stage prostate cancer.
Study II (Abstract no. 210)
Study title: "Comparing the Overall Survival of Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel, a Vaccine Admixed with one Costimulatory Molecule, and a Vaccine with Three Costimulatory Molecules."
In this National Cancer Insti
|SOURCE BN ImmunoTherapeutics|
Copyright©2009 PR Newswire.
All rights reserved